Web of Science: 11 citations, Scopus: 12 citations, Google Scholar: citations,
TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population
Martínez-Escudé, Alba (Institut Català de la Salut. Centre d'Atenció Primària La Llagosta)
Pera, Guillem (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Costa-Garrido, Anna (Universitat Autònoma de Barcelona)
Rodríguez, Lluís (Institut Català de la Salut)
Arteaga, Ingrid (Institut Català de la Salut)
Expósito, Carmen (Institut Català de la Salut. Centre d'Atenció primària Badia del Vallès)
Torán Montserrat, Pere (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Caballería, Llorenç (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)

Date: 2021
Abstract: Thyroid hormones may be a risk factor for the development of non-alcoholic fatty liver disease (NAFLD) and its progression to liver fibrosis. The aim of this study is to investigate the relationship between thyroid stimulating hormone (TSH) levels, NAFLD, and liver fibrosis in the general population. A descriptive cross-sectional study was performed in subjects aged 18-75 years randomly selected from primary care centers between 2012 and 2016. Each subject underwent clinical evaluation, physical examination, blood tests and transient elastography. Descriptive and multivariate logistic regression analyses were used to identify factors associated with NAFLD and fibrosis. We included 2452 subjects (54 ± 12 years; 61% female). Subjects with TSH ≥ 2. 5 μIU/mL were significantly associated with obesity, atherogenic dyslipidemia, metabolic syndrome (MetS), hypertransaminasemia and altered cholesterol and triglycerides. The prevalence of NAFLD and liver fibrosis was significantly higher in subjects with TSH ≥ 2. 5 (μIU/mL). We found a 1. 5 times increased risk of NAFLD, 1. 8 and 2. 3 times increased risk of liver fibrosis for cut-off points of ≥8. 0 kPa and ≥9. 2 kPa, respectively, in subjects with TSH ≥ 2. 5 μIU/mL compared with TSH < 2. 5 μIU/mL (control group), independent of the presence of MetS. These findings remained significant when stratifying TSH, with values ≥ 10 μIU/mL.
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès
Document: Article ; recerca ; Versió publicada
Subject: Thyroid stimulating hormone ; Thyroid function ; Metabolic syndrome ; Obesity ; Liver fibrosis ; Transient elastography ; Non-alcoholic fatty liver disease
Published in: Journal of clinical medicine, Vol. 10, Issue 13 (June 2021) , art. 2907, ISSN 2077-0383

DOI: 10.3390/jcm10132907
PMID: 34209831


15 p, 1023.9 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles

 Record created 2022-03-06, last modified 2024-03-28



   Favorit i Compartir